Sign in or create an account to add this stock to your watchlist.
About Merus (NASDAQ:MRUS)
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer. Its pre-clinical bispecific antibody candidates include MCLA-134 and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Incyte and ONO Pharmaceutical Co., Ltd. to develop bispecific antibody candidates based on Biclonics technology platform; collaboration agreement with Ono Pharmaceutical Co., Ltd. for the development of human bispecific antibodies; and strategic research collaboration agreement with the Vall d'Hebron Institute of Oncology to develop novel agents for therapeutic applications. Merus N.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRUS
CUSIPN/A
Phone31-30-253-8800
Debt
Debt-to-Equity RatioN/A
Current Ratio10.05
Quick Ratio10.05
Price-To-Earnings
Trailing P/E Ratio-4.22
Forward P/E Ratio-4.90
P/E GrowthN/A
Sales & Book Value
Annual Sales$15.36 million
Price / Sales26.52
Cash FlowN/A
Price / CashN/A
Book Value$2.79 per share
Price / Book6.45
Profitability
EPS (Most Recent Fiscal Year)($4.29)
Net Income$-82,610,000.00
Net Margins-530.70%
Return on Equity-91.14%
Return on Assets-28.35%
Miscellaneous
Employees51
Outstanding Shares22,630,000
Merus (NASDAQ:MRUS) Frequently Asked Questions
What is Merus' stock symbol?
Merus trades on the NASDAQ under the ticker symbol "MRUS."
How were Merus' earnings last quarter?
Merus (NASDAQ:MRUS) released its earnings results on Thursday, April, 26th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter. The biotechnology company earned $4.49 million during the quarter. Merus had a negative net margin of 530.70% and a negative return on equity of 91.14%. View Merus' Earnings History.
When is Merus' next earnings date?
What price target have analysts set for MRUS?
3 equities research analysts have issued 12-month price objectives for Merus' stock. Their predictions range from $28.00 to $32.00. On average, they anticipate Merus' share price to reach $30.00 in the next year. View Analyst Ratings for Merus.
Who are some of Merus' key competitors?
Some companies that are related to Merus include Cambrex (CBM), ARMO BioSciences (ARMO), PTC Therapeutics (PTCT), Innoviva (INVA), Zogenix (ZGNX), Radius Health (RDUS), Pacira Pharmaceuticals (PCRX), ImmunoGen (IMGN), Apellis Pharmaceuticals (APLS), Endo International (ENDP), TherapeuticsMD (TXMD), Impax Laboratories (IPXL), Theravance Biopharma (TBPH), Myovant Sciences (MYOV) and Mallinckrodt (MNK).
Who are Merus' key executives?
Merus' management team includes the folowing people:
- Dr. Ton Logtenberg Ph.D., Co-Founder, CEO & Exec. Director (Age 60)
- Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific Advisor
- Mr. John J. Crowley, CFO & Exec. VP (Age 44)
- Mr. John de Kruif Ph.D., CTO & Sr. VP
- Mr. Mark Throsby Ph.D., Chief Scientific Officer & Exec. VP (Age 51)
When did Merus IPO?
(MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.
Has Merus been receiving favorable news coverage?
Media coverage about MRUS stock has trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Merus earned a news impact score of 0.09 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 44.58 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Merus' major shareholders?
Merus' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include
BIOTECHNOLOGY VALUE FUND L P
(10.80%), BVF Inc. IL (10.69%), Sofinnova Ventures Inc (8.67%), Rock Springs Capital Management LP (0.77%), Iguana Healthcare Management LLC (0.33%) and Stanley Laman Group Ltd. (0.24%). View Institutional Ownership Trends for Merus.
Which institutional investors are selling Merus stock?
MRUS stock was sold by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP and Iguana Healthcare Management LLC. View Insider Buying and Selling for Merus.
Which institutional investors are buying Merus stock?
MRUS stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Sofinnova Ventures Inc, Stanley Laman Group Ltd. and Millennium Management LLC. View Insider Buying and Selling for Merus.
How do I buy shares of Merus?
Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merus' stock price today?
One share of MRUS stock can currently be purchased for approximately $18.00.
How big of a company is Merus?
Merus has a market capitalization of $405.21 million and generates $15.36 million in revenue each year. The biotechnology company earns $-82,610,000.00 in net income (profit) each year or ($4.29) on an earnings per share basis. Merus employs 51 workers across the globe.
How can I contact Merus?
Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-30-253-8800 or via email at [email protected]
MarketBeat Community Rating for Merus (MRUS)
MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote "Outperform" if you believe MRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Merus (NASDAQ:MRUS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Merus in the last 12 months. Their average twelve-month price target is $30.00, suggesting that the stock has a possible upside of 66.67%. The high price target for MRUS is $32.00 and the low price target for MRUS is $28.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.50 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $30.00 | $30.00 | $30.25 | $30.25 |
| Price Target Upside: | 66.67% upside | 57.15% upside | 58.46% upside | 85.81% upside |
Merus (NASDAQ:MRUS) Consensus Price Target History
Merus (NASDAQ:MRUS) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Merus (NASDAQ:MRUS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Merus (NASDAQ MRUS) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 43.74%
Merus (NASDAQ MRUS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Merus (NASDAQ MRUS) News Headlines
| Source: |
|
Merus (NASDAQ:MRUS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Merus (NASDAQ:MRUS) Income Statement, Balance Sheet and Cash Flow Statement
Merus (NASDAQ MRUS) Stock Chart for Monday, May, 21, 2018
Loading chart…
